Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV

被引：8

作者：

Akhavan, S. ^{[3
,4
]}

Schnuriger, A. ^{[3
,4
]}

Lebray, P. ^{[1
,2
]}

Benhamou, Y. ^{[1
,2
]}

Poynard, T. ^{[1
,2
]}

Thibault, V. ^{[3
,4
]}

机构：

[1] Univ Paris 06, CNRS, Unite Mixte Rech 8149, Paris, France

[2] Hop La Pitie Salpetriere, AP HP, Dept Hepatogastroenterol, Paris, France

[3] Hop La Pitie Salpetriere, AP HP, Dept Virol, Paris, France

[4] Univ Paris 06, Equipe Rech 1, Paris, France

来源：

JOURNAL OF INFECTIOUS DISEASES | 2009年 / 200卷 / 04期

关键词：

RESISTANCE MUTATIONS; PLUS RIBAVIRIN; VARIANTS; INHIBITORS; NS5B;

D O I：

10.1086/600893

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To analyze the genetic diversity of the NS3 gene in patients infected with hepatitis C virus (HCV) genotype 4 (HCV-4) and to assess the possible effects of the gene polymorphism (or variability) on drug susceptibility, 43 NS3 gene sequences were determined for 53 selected patients with HCV-4 infection. NS3 sequencing, like NS5B sequencing, allowed correct subtype determination. Most residues that were located within the catalytic triad or the NS4-binding region or that were involved in metal binding were highly conserved and identical to those found in HCV genotype 1. Compared with HCV genotype 1, all HCV-4 NS3 protein presented V36L and C16T residue changes that could potentially reduce antiprotease activity. The efficacy of antiprotease in HCV-4-infected patients remains to be proven in large clinical trials.

引用

页码：524 / 527

页数：4

共 14 条

[1] Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects [J].

Bartels, Doug J. ;

Zhou, Yi ;

Zhang, Eileen Z. ;

Marcial, Michelle ;

Byrn, Randal A. ;

Pfeiffer, Thomas ;

Tigges, Ann M. ;

Adiwijaya, Bambang S. ;

Lin, Chao ;

Kwong, Ann D. ;

Kieffer, Tara L. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (06) :800-807

[2] Review article: novel therapeutic options for chronic hepatitis C [J].

Cholongitas, E. ;

Papatheodoridis, G. V. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (10) :866-884

[3] Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response [J].

Kamal, Sanaa M. ;

El Kamary, Samer S. ;

Shardell, Michelle D. ;

Hashem, Mohamed ;

Ahmed, Imad N. ;

Muhammadi, Mohamed ;

Sayed, Khahfa ;

Moustafa, Ashraf ;

Hakem, Sarah Abdel ;

Ibrahiem, Amany ;

Moniem, Mohamed ;

Mansour, Hoda ;

Abdelaziz, Mohamed .

HEPATOLOGY, 2007, 46 (06) :1732-1740

[4] Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients [J].

Kuntzen, Thomas ;

Timm, Joerg ;

Berical, Andrew ;

Lennon, Niall ;

Berlin, Aaron M. ;

Young, Sarah K. ;

Lee, Bongshin ;

Heckerman, David ;

Carlson, Jonathan ;

Reyor, Laura L. ;

Kleyman, Marianna ;

McMahon, Cory M. ;

Birch, Christopher ;

Wiesch, Julian Schulze zur ;

Ledlie, Timothy ;

Koehrsen, Michael ;

Kodira, Chinnappa ;

Roberts, Andrew D. ;

Lauer, Georg M. ;

Rosen, Hugo R. ;

Bihl, Florian ;

Cerny, Andreas ;

Spengler, Ulrich ;

Liu, Zhimin ;

Kim, Arthr Y. ;

Xing, Yanming ;

Schneidewind, Arne ;

Madey, Margaret A. ;

Fleckenstein, Jaquelyn F. ;

Park, Vicki M. ;

Galagan, James E. ;

Nusbaum, Chad ;

Walker, Bruce D. ;

Lake-Bakaar, Gerond V. ;

Daar, Eric S. ;

Jacobson, Ira M. ;

Gomperts, Edivard D. ;

Edlin, Brian R. ;

Donfield, Sharyne M. ;

Chung, Raymond T. ;

Talal, Andrew H. ;

Marion, Tony ;

Birren, Bruce W. ;

Henn, Mattliew R. ;

Allen, Todd M. .

HEPATOLOGY, 2008, 48 (06) :1769-1778

[5] Comparison of hepatitis C virus NS5b and 5′ noncoding gene sequencing methods in a multicenter study [J].

Laperche, S ;

Lunel, F ;

Izopet, J ;

Alain, S ;

Dény, P ;

Duverlie, G ;

Gaudy, C ;

Pawlotsky, JM ;

Plantier, JC ;

Pozzetto, B ;

Thibault, V ;

Tosetti, F ;

Lefrère, JL .

JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (02) :733-739

[6]

López-Labrador FX, 2008, ANTIVIR THER, V13, P481

[7] Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C [J].

Reiser, M ;

Hinrichsen, H ;

Benhamou, Y ;

Reesink, HW ;

Wedemeyer, H ;

Avendano, C ;

Riba, N ;

Yong, CL ;

Nehmiz, G ;

Steinmann, GG .

HEPATOLOGY, 2005, 41 (04) :832-835

[8] Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection [J].

Roulot, D. ;

Bourcier, V. ;

Grando, V. ;

Deny, P. ;

Baazia, Y. ;

Fontaine, H. ;

Bailly, F. ;

Castera, L. ;

De Ledinghen, V. ;

Marcellin, P. ;

Poupon, R. ;

Bourliere, M. ;

Zarski, J. P. ;

Roudot-Thoraval, F. .

JOURNAL OF VIRAL HEPATITIS, 2007, 14 (07) :460-467

[9] Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes [J].

Simmonds, P ;

Bukh, J ;

Combet, C ;

Deléage, G ;

Enomoto, N ;

Feinstone, S ;

Halfon, P ;

Inchauspé, G ;

Kuiken, C ;

Maertens, G ;

Mizokami, M ;

Murphy, DG ;

Okamoto, H ;

Pawlotsky, JM ;

Penin, FO ;

Sablon, E ;

Tadasu, SI ;

Stuyver, L ;

Thiel, HJ ;

Viazov, S ;

Weiner, A ;

Widell, A .

HEPATOLOGY, 2005, 42 (04) :962-973

[10] MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0 [J].

Tamura, Koichiro ;

Dudley, Joel ;

Nei, Masatoshi ;

Kumar, Sudhir .

MOLECULAR BIOLOGY AND EVOLUTION, 2007, 24 (08) :1596-1599

← 1 2 →